Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation.
Zhuo YuHai FengYunhui ZhuoMan LiXiaojun ZhuLingying HuangXin ZhangZhenhua ZhouChao ZhengYun JiangFan LeDae-Yeul YuAlfred Szelok ChengXuehua SunYueqiu GaoPublished in: Cellular oncology (Dordrecht) (2020)
Our results indicate that bufalin acts as a potential anti-HCC therapeutic candidate to block HBx-induced AR/CCRK/β-catenin signaling by targeting AR and CCRK, which may provide a novel strategy for the treatment of HBV-associated HCC.